Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michel Barakat

Emergency Medicine Bountiful, UT Medical Doctor

NPI 1134411341 CMS profile 1383556

3837 Huntington Dr, Ste 101, Bountiful, UT 84010

Open in the dashboard

General payments

$29,610

211 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$15,931 paid to institutions, not to them · program years 2021–2024

Through program year 2025, Michel Barakat of Bountiful, UT is reported in the CMS Open Payments database as having received $29,610 across 211 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $15,931 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,626 7
2024 General $3,544 25
2023 General $4,196 45
2022 General $2,776 34
2021 General $465 8
2020 General $620 13
2019 General $16,384 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michel Barakat
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to Michel Barakat were reported at $1,626. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year Michel Barakat Emergency Medicine median Middle half National median
2019 $16,384 $51 $18–$128 $163
2020 $620 $29 $16–$99 $114
2021 $465 $40 $18–$124 $132
2022 $2,776 $49 $20–$134 $149
2023 $4,196 $51 $22–$142 $160
2024 $3,544 $52 $22–$150 $164
2025 $1,626 $57 $24–$150 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $8,703 46 payments
  2. Medtronic, Inc. $7,522 55 payments
  3. Biotronik Inc. $3,956 19 payments
  4. Boston Scientific Corporation $3,724 26 payments
  5. Abbott Laboratories $3,449 36 payments
  6. Cook Incorporated $571 1 payment
  7. Cook Medical LLC $525 6 payments
  8. Cardiva Medical, Inc. $384 6 payments
  9. Impulse Dynamics (USA) Inc. $378 6 payments
  10. CVRx, Inc. $182 3 payments
  11. Other $217 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $22,106 68 payments
  2. Food and Beverage $7,505 143 payments
Products named General payments · program years 2019–2025
  1. Arctic Front $2,251 9 payments
  2. AVEIR $1,999 13 payments
  3. General Therapies $1,403 5 payments
  4. WATCHMAN $1,184 2 payments
  5. MICRA $800 10 payments
  6. CARDIOBLATE CRYOFLEX $653 6 payments
  7. ENSITE PRECISION $651 9 payments
  8. ARCTIC FRONT ADVANCE $640 4 payments
  9. WATCHMAN Access System $635 5 payments
  10. Cook Medical Lead Extraction $571 1 payment
  11. Other $4,613 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

58

Median for Cardiology: 2,533

Drug cost

$16,162

Median for Cardiology: $485,213

Branded share of claims

25.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 15 $15,664
Metoprolol Succinate Generic 29 $409
Doxycycline Monohydrate Generic 14 $89

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$252,917

Medicare's payments for the services billed

Medicare patients

897

Average age 79

Services billed

3,892

352 women, 545 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 65%
Ischemic heart disease 53%
Heart failure 46%
Arthritis 42%
Chronic kidney disease 32%
Diabetes 28%
Depression 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

211 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medicine in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record